Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 8/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 8/20 | 0.50 |
| ▸ | ITGAL | P20701 | 8/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837759 | 0.87 | ITGB2 (0.53) | ITGB2ICAM1ITGALTNFHTR2A | |
| SCHEMBL837864 | 0.85 | TNF (0.68) | ITGB2ICAM1ITGALTNFNR4A2 | |
| SCHEMBL836657 | 0.85 | TNF (0.68) | ITGB2ICAM1ITGALTNFNR4A2 | |
| SCHEMBL24328355 | 0.81 | SMN1; SMN2 (0.61) | ITGB2ICAM1ITGALTNFHTR2A | |
| SCHEMBL3467251 | 0.80 | TNF (0.64) | TNFHTR2ANR4A2RIPK1ALOX15 | |
| SCHEMBL18028962 | 0.80 | TNF (0.64) | TNFHTR2ANR4A2RIPK1ALOX15 | |
| SCHEMBL30495964 | 0.80 | TNF (0.64) | TNFHTR2ANR4A2RIPK1ALOX15 | |
| SCHEMBL837413 | 0.80 | TNF (0.64) | TNFHTR2ANR4A2RIPK1ALOX15 | |
| SCHEMBL838121 | 0.80 | TNF (0.64) | TNFHTR2ANR4A2RIPK1ALOX15 | |
| SCHEMBL31407308 | 0.79 | ACE (0.56) | ITGB2ICAM1ITGALTNFACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071243-A1 | BIOLOGICAL PRODUCTION OF TRYPTOPHAN-DERIVED PRODUCTS | TPH1, TPH2, SLC6A4 | ITGB2 4874/4885ICAM1 4827/4885ITGAL 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.